{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:07:31Z","timestamp":1791857251799,"version":"4.3.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:00:00Z","timestamp":1543017600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,11,24]]},"DOI":"10.3233\/jhd-180293","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T13:07:41Z","timestamp":1532092061000},"page":"355-366","source":"Crossref","is-referenced-by-count":98,"title":["Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders"],"prefix":"10.1177","volume":"7","author":[{"given":"Karen E.","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Department of Neurology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Duijn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Leiden University Medical Centre, Leiden; and Mental Health Care Centre Delfland, Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Craufurd","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK"},{"name":"St Mary\u2019s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Drazinic","sequence":"additional","affiliation":[{"name":"Chief Medical Officer of State Mental Health Facilities, Office of Substance Abuse and Mental Health Florida Department of Children and Families, Tallahassee, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Edmondson","sequence":"additional","affiliation":[{"name":"HD Reach, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Goodman","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Drug Works, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"van Kammen","sequence":"additional","affiliation":[{"name":"Consultant for CNS drug development, Professor emeritus University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Loy","sequence":"additional","affiliation":[{"name":"Westmead Huntington Disease Service, The University of Sydney, and the Garvan Institute of Medical Research, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Charit\u00e9 - Universit\u00e4tsmedizin, Berlin, Germany and University of Edinburgh and UK DRI, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaVonne Veatch","family":"Goodman","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Drug Works, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-180293_ref1","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.3233\/JHD-180293_ref2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","article-title":"Neuropsychiatric aspects of Huntington\u2019s disease","volume":"71","author":"Paulsen","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-180293_ref3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/nmt.15.45","article-title":"Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease","volume":"5","author":"van Wamelen","year":"2015","journal-title":"Neurodegener Dis Manag"},{"key":"10.3233\/JHD-180293_ref4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.genhosppsych.2007.11.005","article-title":"Behavioural problems in Huntington\u2019s disease using the Problem Behaviours Assessment","volume":"30","author":"Kingma","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.3233\/JHD-180293_ref5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp.2009.181149","article-title":"Factor analysis of behavioural symptoms in Huntington\u2019s disease","volume":"82","author":"Rickards","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-180293_ref6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0924-9338(01)00604-6","article-title":"Huntington\u2019s disease: A review of the literature on prevalence and treatment of neuropsychiatric phenomena","volume":"16","author":"Naarding","year":"2001","journal-title":"Eur Psychiatry"},{"key":"10.3233\/JHD-180293_ref7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2012.10.020","article-title":"Prefrontal activity in Huntington\u2019s disease reflects cognitive and neuropsychiatric disturbances: The IMAGE-HD study","volume":"239","author":"Gray","year":"2013","journal-title":"Exp Neurol"},{"key":"10.3233\/JHD-180293_ref8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington\u2019s disease-associated chorea","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JHD-180293_ref9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/jnp.2010.22.3.287","article-title":"Correlates of apathy in Huntington\u2019s disease","volume":"22","author":"van Duijn","year":"2010","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JHD-180293_ref10","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: An evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JHD-180293_ref11","doi-asserted-by":"crossref","unstructured":"Mestre T , Ferreira J , Coelho MM , Rosa M , Sampaio C .Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev. 2009;CD006456.","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"10.3233\/JHD-180293_ref12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","article-title":"An evidence-based approach in the treatment of Huntington\u2019s disease","volume":"18","author":"Mestre","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-180293_ref13","doi-asserted-by":"crossref","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","article-title":"Bupropion for the treatment of apathy in Huntington\u2019s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial","volume":"12","author":"Gelderblom","year":"2017","journal-title":"PLoS One"},{"key":"10.3233\/JHD-180293_ref14","doi-asserted-by":"crossref","DOI":"10.17226\/13058","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Graham","year":"2011"},{"key":"10.3233\/JHD-180293_ref15","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"key":"10.3233\/JHD-180293_ref16","doi-asserted-by":"crossref","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington\u2019s disease","volume":"3","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.3233\/JHD-180293_ref17","doi-asserted-by":"crossref","first-page":"RRN1261","DOI":"10.1371\/currents.RRN1261","article-title":"An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington\u2019s disease","volume":"3","author":"Anderson","year":"2011","journal-title":"PLoS Curr"},{"key":"10.3233\/JHD-180293_ref18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington\u2019s Disease","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JHD-180293_ref19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0447.1991.tb05511.x","article-title":"The clinical manifestation of mental disorder in Huntington\u2019s disease: A retrospective case record study of disease progression","volume":"83","author":"Pflanz","year":"1991","journal-title":"Acta Psychiatr Scand"},{"key":"10.3233\/JHD-180293_ref20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.10.3.314","article-title":"Apathy is not depression","volume":"10","author":"Levy","year":"1998","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JHD-180293_ref21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1176\/jnp.14.1.37","article-title":"Behavior in Huntington\u2019s disease: Dissociating cognition-based and mood-based changes","volume":"14","author":"Thompson","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JHD-180293_ref22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00005053-199001000-00004","article-title":"Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease","volume":"178","author":"Burns","year":"1990","journal-title":"J Nerv Ment Dis"},{"key":"10.3233\/JHD-180293_ref23","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias. Second edition","volume":"164","author":"Rabins","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JHD-180293_ref24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JHD-180293_ref25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5334\/tohm.231","article-title":"The many facets of unawareness in huntington disease","volume":"4","author":"McCusker","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"key":"10.3233\/JHD-180293_ref26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-140109","article-title":"Unawareness of deficits in Huntington\u2019s disease","volume":"3","author":"Sitek","year":"2014","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-180293_ref27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ap.27.3.160","article-title":"Therapeutic alliance as a measurable psychotherapy skill","volume":"27","author":"Summers","year":"2003","journal-title":"Acad Psychiatry"},{"key":"10.3233\/JHD-180293_ref28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0033-3182(00)71170-4","article-title":"Neuropsychiatry of Huntington\u2019s disease and other basal ganglia disorders","volume":"41","author":"Rosenblatt","year":"2000","journal-title":"Psychosomatics"},{"key":"10.3233\/JHD-180293_ref29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington\u2019s disease. Huntington Study Group","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JHD-180293_ref30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-180293_ref31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/ajp.140.6.728","article-title":"Psychiatric syndromes in Huntington\u2019s disease","volume":"140","author":"Caine","year":"1983","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JHD-180293_ref32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/mds.1225","article-title":"Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders","volume":"16","author":"Kulisevsky","year":"2001","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-180293_ref33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000091523","article-title":"Cognitive impairment related to apathy in early Huntington\u2019s disease","volume":"21","author":"Baudic","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JHD-180293_ref34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JHD-180293_ref35","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-180293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:39Z","timestamp":1777452639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-180293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,24]]},"references-count":35,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jhd-180293","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,24]]}}}